Health care ETFs have diverged sharply as some stocks benefit from the pursuit of virus treatments, others not so much.
Parsing the performance and holdings of different biotech funds.
The volatile segment struggled to catch a break, then rallied, and now sits in the limelight of a virus outbreak.
Fears of Medicare-for-all are weighing on health care ETFs. Is this an opportunity?
How you should trade biotech ETFs.
Health care, internet and oil products have performed well this year.
Losses were as high as 89%.
The segment is delivering some impressive gains after a bout of investor doubt.
Issuers take different approaches to industry and sector exposure.